Immunophenotypic features and t(14;18) (q32;q21) translocation of Chinese follicular lymphomas helps to distinguish subgroups
- Fen Zhang†1,
- Li-Xu Yan†1,
- Su-Xia Lin2,
- Zi-Yin Ye3,
- Heng-Guo Zhuang1,
- Jing-Ping Yun2,
- Han-Liang Lin3,
- Dong-Lan Luo1,
- Fang-Ping Xu1,
- Xin-Lan Luo1,
- Jie Cheng1,
- Ke-Ping Zhang1 and
- Yan-Hui Liu1Email author
© Zhang et al.; licensee BioMed Central Ltd. 2013
Received: 5 May 2013
Accepted: 9 September 2013
Published: 18 September 2013
The revised 2008 World Health Organization classification maintains a histological grading system (grades 1–3) for follicular lymphoma (FL). The value of grading FL has been debated. This study will yield deeper insights into the morphologic, immunophenotypic characterization and t(14;18) translocation in FL and explore their significance of diagnosis of Chinese FL subgroups.
We retrospectively reviewed the FL diagnoses according to the 2008 WHO classification in all diagnostic specimens from a multicentric cohort of 122 Chinese patients. Upon review, 115 cases proved to be truly FL. CD10, BCL6, MUM1, BCL2 and t(14;18) (q32;q21) translocation were detected by Envision immunostaining technique and fluorescence in situ hybridization.
FL1 has larger proportion of follicular pattern (93.0%) than that of FL2 (73.7%, P = 0.036), FL3B (63.6%, P = 0.003) and FL3A (77.4%, P = 0.053), although the last P value was more than 0.05 (Pearson’s chi-squared test). Areas of DLBCL were present in 25.8% (8/31) of FL3A and more frequent in FL3B (59.1%, 13/22; P = 0.015). The positivity of CD10 and BCL2 in FL1-2 were significantly higher than those in FL3 (P < 0.001, P = 0.043, respectively). The positivity of MUM1 in FL1-2 was significantly lower than that in FL3 (10.2% vs. 51.0%; P < 0.001). Furthermore the positivity of MUM1 in FL3A was significantly lower than that in FL3B (37.9% vs. 68.2%; P = 0.032). The positivity of t(14;18) was higher in FL1-2 than in FL3 (73.5% vs. 35.6%, P < 0.001), and was higher in FL3A than in FL3B (51.9% vs. 11.1%, P = 0.005). t(14;18) was significantly correlated with CD10+ (R = 0.453, P < 0.001) and MUM1+ (R = -0.482, P < 0.001).
FL1 and FL2 were immunophenotypically and genomically similar, while FL3A and FL3B were partly immunophenotypically similar but morphologically, genomically distinct. FL3A was genomically closer to FL1-2, whereas FL3A was genomically closer DLBCL. Thus we hypothesize that FL may in fact be a heterogeneous indolent lymphoma encompassing entities with distinct molecular pathogenesis and genetic characteristics. Immunohistochemical and genetic characterization helps to distinguish subgroups of FLs.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1334018129864616.
KeywordsFollicular lymphoma CD10 BCL6 MUM1 BCL2 Immunophenotype t(14;18) (q32;q21) translocation
Follicular lymphoma (FL) is an indolent lymphoma. It accounts for 22% of non-Hodgkin’s lymphoma and it is by far the most frequent indolent lymphoma . It is mainly composed of centrocytes with a variable component of centroblasts, the frequency of which gives the grade (1, 2 or 3, depending on the percentage of centroblasts).
Cluster of differentiation 10 (CD10) and B-Cell Lymphoma 6 (BCL6) are biomarker for centrocytes. Tumor cells in typical FL positively express the two or one of the biomarkers. Some cases, especially grade 3B (FL3B), may lack CD10, but retain BCL6 expression [2–4]. Multiple myeloma oncogene 1 (MUM1) is a marker for late germinal center B cells (GCBs) and early post-GCBs . According to our clinical work and reports ,a few FL are MUM1+. However the significance of expression of MUM1 in FL is still unknown. Most FLs express the anti-apoptotic protein B cell lymphoma 2 (BCL2), while follicles in reactive hyperplasia do not express BCL2. BCL2 positive is an important factor for diagnosis and differential diagnosis of FL.
The t(14;18)(q32;q21) chromosome abnormality is the genetic hallmark of FL. This abnormality juxtaposes the VDJ region of the immunoglobulin heavy chain (IgH) gene on chromosome 14q32 with BCL2 gene on chromosome 18q21, placing BCL2 under the regulatory control of the IgH promotor and causing an overexpression of the BCL2 protein . It is reported [3, 7, 8] that t(14;18) translocation has been detected in only around 13% of FL3B compared to 58-73% in FL3A and more than 85% of FL1-2. There is no correlation between t(14:18) translocation and BCL2 expression .
Several studies have demonstrated that FL exhibits various morphologies, phenotypes, genetic aberrations, and clinical behaviors. These features vary greatly across geographic regions, suggesting geographic heterogeneity as a characteristic of this type of lymphoma. By far, most researches are based on Western population and only a few studies compared the frequency of grade 3A (FL3A) and 3B FL3B cases. Therefore, this study was undertaken to reveal the morphological, immunophenotypic and genetic features of FLs in China. We also investigated the relationship between t(14:18) translocation and the histological grade, as well as the biomarker expression profile of CD10, BCL6, MUM1 and BCL2.
Biopsy material from 122 unselected cases of FL was retrieved from the surgical pathology and consultation files at Guangdong General Hospital (Guangzhou, China), Sun Yat-sen University Cancer Center (Guangzhou, China), and the First Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) between 2001 and 2010. Archival diagnostic paraffin blocks were available for all cases. The tissue was fixed in 10% neutral buffered formalin, embedded in paraffin, and processed routinely. Four-micrometer sections were stained with H&E for routine histologic evaluation. The histopathology of all cases was reviewed by two of qualified pathologists (Yan-Hui Liu and Heng-Guo Zhuang). Cases were evaluated and graded according to 2008 World Health Organization (WHO) criteria. Upon review, 115 cases proved to be truly FL, and 7 cases were excluded (1 reactive disease, 3 diffuse large B-cell lymphomas, and 3 other types of low-grade B-cell lymphoma). The ethics committee of Guangdong General Hospital & Guangdong Academy of Medical Science approved the study [Reference number No.GDREC2010147H].
Immunohistochemistry staining was performed using Real Envision Kit (K5007, DAKO, Carpinteria, CA) on an automated immunostaining module (DAKO) according to the manufacturer’s instructions. The antibodies and dilutions employed were as follows: CD10, clone 56C6, 1:100 dilution (Novocastra, Newcastle, UK); BCL2, clone 124, 1:50 dilution (DAKO); BCL6, clone PG-B6p, 1:100 dilution (DAKO); and MUM1, clone MUM1p, 1:400 dilution (DAKO). A negative control was performed in all cases by omitting the primary antibody, which in all instances resulted in negative immunoreactivity. In all cases, internal control was used as positive control.
Only tumor tissues with distinct nuclear staining for BCL6 and MUM1 in >30% of the tumor cells were recorded as positive. Distinct membrane staining for CD10 in > 30% of tumor cells and cytoplasm staining for BCL2 in > 30% of tumor cells was recorded.
Fluorescence In Situ Hybridization (FISH)
FISH for t(14;18) (q32;q21) was performed on formalin-fixed, paraffin-embedded tissue sections as previously described  using a dual-fusion LSI IGH/BCL2 probe (08L60-020, Vysis, Downers Grove, IL). FISH signals were analyzed using a fluorescence microscope (Olympus BX51, Tokyo, Japan) equipped with a DP72 camera and DP2-BSW software (Olympus, Tokyo, Japan).
Statistical analysis was prepared using the Statistical Package of Social Sciences version 18.0 for Windows (SPSS, Chicago, IL). To compare pattern proportions of each histologic grade group, we performed Pearson’s chi-squared test using a R × 2 contingency table. Because the proportions of follicular and diffuse pattern, and focally follicular pattern in each group were small, we analyzed the two groups together as one group. We performed Pearson’s Chi-square test and Fisher’s exact test to compare the incidence of marker expressions and positive t(14;18) in each histologic grade group. Spearman’s rank correlation was used in correlation analysis. Results were considered statistically significant when two-sided P < 0.05.
The median age of 115 patients with FL at diagnosis was 55 years (range, 22–86 years). Males were more affected than females, with a male-to-female ratio of 1.4:1 (67:48). FL predominantly involved lymph nodes (100/115, 87.0%), but also spleen (3/115, 2.6%) and Waldeyer ring (5/115, 4.3%). The gastrointestinal tract cases involved 3 (2.6%) stomach and 1 (0.9%) ileocecal junction. Occasionally, FL involved parotid (2/115, 1.7%), and thyroid gland (1/115, 0.9%).
The patterns and grading of 115 FLs
FL1 (N = 43)
FL2 (N = 19)
FL3A (N = 31)
FL3B (N = 22)
Follicular and diffuse
Focally follicular/predominantly diffuse
The patterns of high-grade FLs
FL3A (N = 31)
FL3B (N = 22)
DLBCL with FL3#
CD10, BCL6 and MUM1 protein expression the FL subgroups
< 0.001 *
< 0.001 *
< 0.001 *
The positive rate of MUM1 in low grade was significantly lower than that in high grade (10.2% vs. 51.0%, P < 0.001; Figure 2, Table 3). Similar difference was found between FL1-2 and FL3A (10.2% vs. 37.9%, P = 0.002), FL3A and FL3B (37.9% vs. 68.2%, P = 0.032). However, there was no statistical difference in MUM1 expression between FL1 and FL2 (Table 3).
BCL2 protein expression and t(14;18) translocation in the FL subgroups
t(14;18) translocation positive
< 0.001 *
< 0.001 *
Correlation between CD10 and MUM1 protein expression in the FL
Relationship among histological grades, immunophenotyping and t(14;18) translocation by FISH analysis
t(14;18)(q32;q21) (IGH/BCL2) translocation analysis by FISH was successfully done in 94 of 115 FL cases. Representative positive FISH image are shown in Figure 1. The total positive rate of t(14;18) translocation was 55.3% (52/94). The t(14;18) translocation rate in low grade was much higher than that in high grade (73.5% vs. 35.6%, P < 0.001). The t(14;18) translocation rate in FL3A was much higher than that in FL3B (51.9% vs. 11.1%, P = 0.005; Table 4).
The correlation between FL grading and t(14;18) translocation and BCL2
The correlation of FL immunophenotyping and t(14;18) translocation
Positive t(14;18) translocation
FL is the most common of the indolent non-Hodgkin’s lymphomas, and the second-most-common form of non-Hodgkin’s lymphomas overall. Chinese FL had its unique epidemiological and clinicalopathological features. This study demonstrated a high proportion of FL3 (46.1%), which was very close to a previous report (45.7%) on Chinese cohort , but higher than that in western countries . According to a nationwide multicenter study of 10002 cases , FL accounts for about 5.5% of all lymphomas in China. The incidence was close to those in Asia and in developing countries, but much lower than those in USA and Western Europe [13, 14]. In published studies [15, 16], areas of DLBCL are present in 60-80% of FL3B cases and less frequently in FL3A. Our results are very close to those data.
FL is a neoplasm composed of germinal center (GC) B-cells (typically both ceotrocytes and centroblasts cells). FL cells typically express B-cell markers (CD19, CD20, CD22, and CD79a), together with GC-markers (CD10 and BCL6) and BCL2 [11, 17]. Some cases, especially FL3B, may lack CD10, but retain BCL6 expression [2–4]. In our FL study CD10 positive rate significantly reduced in high-grade FL compared with low-grade FL, Whereas BCL6 seems to be a more reliable GC-marker than CD10, as it is conserved in higher grade .
MUM1 is a marker for late germinal center B cells (GCBs) and early post-GCBs . In our FL series GC-marker CD10 decreased with the increase of FL grade, while post-GC marker MUM1 increased with the increase of FL grade. There were eleven CD10-/MUM1+ cases, of which ten were high grade and one was low grade. The only one low-grade case was morphologically composed of large central cells, and was t(14;18) translocation negative. This was consisted with the previous report that FL composed of large central cells is more aggressive than other low-grade FL, and had lower CD10-positive rate and t(14;18) translocation rate . The proportion of CD10-/MUM1+ cases in CD10- FL rose from 55.0% to 80.0% if the cut-off value for MUM1 positive decreased from 30% to 10%. Hans’ algorithm  has been widely used as standard to sub-classify DLBCL into (GCB) and non-GCB origins . If classified according to Hans’s algorithm, 80% (16/20) of CD10- FL were NONnon-GCB subtype and the remaining 20% (4/20) were GCB subtype, indicating possible different origins of CD10-/MUM1+ and CD10-/MUM1- FLs.
BCL2 is a well-known anti-apoptotic protein. Bcl-2 expressed in 91.0% of our FL cases, which falls at the higher end of the reported range of 75-98% [20–22]. Besides, BCL2 protein is expressed by a variable proportion of the tumor cells in 85-90% of cases of low-grade FL, but only 50% of high-grade FL using standard antibodies . Therefore, in clinical work it must be recognized that absence of BCL2 protein dose not exclude FL. In this study, we found that BCL2 was consistently strong in the tumor cells in low-grade FLs, but was inconsistently medium to negative in grade 3 FLs. Whether this is conducive to the diagnosis of high-grade FL needs to be verified by more cases.
The t(14;18) translocation rate in FL1-2 in this study was 73.5%, which was close to Japanese data [23, 24], and slightly lower than most of the western reports (80-90%) . This difference may be caused by regional and ethnical differences. The t(14;18) translocation rate in FL3A (51.9%) was close to that in low-grade FL (73.5%). While the rate in FL3B (11.1%) was close to those reported in DLBCL  and our previous study . It was reported  that FLs without t(14;18) are usually histological FL3B. This may suggest that FLs without the t(14;18) are pathophysiologically distinct from those cases with BCL2 translocation.
The t(14;18)(q32;q21) translocation results in juxtaposition of the IgH and bcl-2 genes, and causes overexpression of BCL2, which prevents cells in follicular center from undergoing apoptosis . However, this study demonstrated no correlation between t(14;18) translocation and BCL2 expression. Absence of BCL2 protein in t(14;18)+/BCL2- cases is partly due to mutations in the BCL2 gene that eliminate the epitopes recognized by the most commonly used antibody . For t(14;18)-/BCL2+ cases, other molecular mechanisms, for example other types of chromosomal alterations involving the BCL2 gene on chromosome 18, activation of NF-κB signaling pathway, viral infections, cytokine effects and interactions with cell cycle regulators [6, 29]. In this study, the consistent rate of t(14;18) translocation and BCL2 expression decreased with the increase of grading. 83.3% of FL3B were t(14;18) translocation-/BCL2+, suggesting a potential different pathogenesis compared with FL3A (34.6%) and FL1-2 (21.7%).
The value of grading FL has been debated since the 1980s. The 2008 WHO grades classification maintains a histological grading system (grades 1–3) for FL. It has been suggested that the number of grades could be reduced, since FL1 and FL2 are clinically indolent and pathologically similar. Our study revealed that low-grade FL had a high homogeneity in morphology, immune phenotype and t(14;18) translocation. FL3A and FL3B showed significant heterogeneity in t(14;18) translocation and MUM1 expression, although both types showed certain homogeneity in morphology and immunophenotype (CD10, BCL2 and BCL6). Consistent with previous studied [16, 30], FL3A was genetically similar to low-grade FL, while FL3B was more similar to DLBCL in t(14;18) translocation.
In conclusion, our study revealed that FL1 and FL2 were immunophenotypically and genomically similar, while FL3A and FL3B were partly immunophenotypically similar but morphologically, genomically distinct. FL3A was genomically closer to FL1-2, whereas FL3A was genomically closer DLBCL. CD10- FL was correlated with MUM1+ and t(14;18)-,suggesting its potentially different origin or pathogenesis from other subgroups. Thus we hypothesize that FL may in fact be a heterogeneous indolent lymphoma encompassing entities with distinct molecular pathogenesis and genetic characteristics. Immunohistochemical and genetic characterization helps to distinguish subgroups of FLs.
World health organization
FL grade 1
FL grade 2
Low grade FL
FL grade 3, high grade FL
FL grade 3A
FL grade 3B
Cluster of differentiation 10
B Cell Lymphoma 6
Multiple myeloma oncogene 1
Germinal center B cell
B cell lymphoma 2
Fluorescence In Situ Hybridization
- Groves FD, Linet MS, Travis LB, Devesa SS: Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000, 92 (15): 1240-1251. 10.1093/jnci/92.15.1240.View ArticlePubMedGoogle Scholar
- Bosga-Bouwer AG, van den Berg A, Haralambieva E, de Jong D, Boonstra R, Kluin P, van den Berg E, Poppema S: Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma?. Human pathology. 2006, 37 (5): 528-533. 10.1016/j.humpath.2005.12.005.View ArticlePubMedGoogle Scholar
- Karube K, Guo Y, Suzumiya J, Sugita Y, Nomura Y, Yamamoto K, Shimizu K, Yoshida S, Komatani H, Takeshita M, Kikuchi M, Nakamura N, Takasu O, Arakawa F, Tagawa H, Seto M, Ohshima K: CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood. 2007, 109 (7): 3076-3079.PubMedGoogle Scholar
- Ott G, Katzenberger T, Lohr A, Kindelberger S, Rudiger T, Wilhelm M, Kalla J, Rosenwald A, Muller JG, Ott MM, Muller-Hermelink HK: Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood. 2002, 99 (10): 3806-3812. 10.1182/blood.V99.10.3806.View ArticlePubMedGoogle Scholar
- Carbone A, Gloghini A, Aldinucci D, Gattei V, Dalla-Favera R, Gaidano G: Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin’s disease. Br J Haematol. 2002, 117 (2): 366-372. 10.1046/j.1365-2141.2002.03456.x.View ArticlePubMedGoogle Scholar
- Papakonstantinou G, Verbeke C, Hastka J, Bohrer M, Hehlmann R: bcl-2 expression in non-Hodgkin’s lymphomas is not associated with bcl-2 gene rearrangements. Br J Haematol. 2001, 113 (2): 383-390. 10.1046/j.1365-2141.2001.02727.x.View ArticlePubMedGoogle Scholar
- Peh SC, Shaminie J, Tai YC, Tan J, Gan SS: The pattern and frequency of t(14;18) translocation and immunophenotype in Asian follicular lymphoma. Histopathology. 2004, 45 (5): 501-510. 10.1111/j.1365-2559.2004.01979.x.View ArticlePubMedGoogle Scholar
- Horn H, Schmelter C, Leich E, Salaverria I, Katzenberger T, Ott MM, Kalla J, Romero M, Siebert R, Rosenwald A, Rosenwald A, Ott G: Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica. 2011, 96 (9): 1327-1334. 10.3324/haematol.2011.042531.PubMed CentralView ArticlePubMedGoogle Scholar
- Einerson RR, Kurtin PJ, Dayharsh GA, Kimlinger TK, Remstein ED: FISH is superior to PCR in detecting t(14;18)(q32;q21)-IgH/bcl-2 in follicular lymphoma using paraffin-embedded tissue samples. Am J Clin Pathol. 2005, 124 (3): 421-429. 10.1309/BLH8MMK85UBQ4K6R.View ArticlePubMedGoogle Scholar
- Chang X, Zu Lan S, Qiu Liang W, Hong Yi G, Jian Chen F, Zhong Jun X, Zhong Zhen G: Clinical and pathological reassessment of 493 cases of non-Hodgkin’s lymphomas according to current WHO classification of lymphoid neoplasms. Chin J Pathol. 2005, 34 (1): 22-27.Google Scholar
- Goteri G, Lucarini G, Zizzi A, Costagliola A, Giantomassi F, Stramazzotti D, Rubini C, Leoni P: Comparison of germinal center markers CD10, BCL6 and human germinal center-associated lymphoma (HGAL) in follicular lymphomas. Diagn Pathol. 2011, 6: 97-10.1186/1746-1596-6-97.PubMed CentralView ArticlePubMedGoogle Scholar
- Xiao Qiu L, Di Gan L, Zi Fen G, Xiao Ge Z, Xiong Zeng Z, Group TCLS: Distribution pattern of lymphoma subtypes in China: A nationwide multicenter study of 10002 cases. J Diagn Concepts Pract. 2012, 11 (2): 111-115.Google Scholar
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW: WHO classification of tumors of haematopoietic and lymphoid tissues. 2008, France: IARC press Lyon, 220-226. 4Google Scholar
- Yang QP, Zhang WY, Yu JB, Zhao S, Xu H, Wang WY, Bi CF, Zuo Z, Wang XQ, Huang J, Dai L, Liu WP: Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol. 2011, 6: 77-10.1186/1746-1596-6-77.PubMed CentralView ArticlePubMedGoogle Scholar
- Hans CP, Weisenburger DD, Vose JM, Hock LM, Lynch JC, Aoun P, Greiner TC, Chan WC, Bociek RG, Bierman PJ, Armitage JO: A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood. 2003, 101 (6): 2363-2367. 10.1182/blood-2002-07-2298.View ArticlePubMedGoogle Scholar
- Katzenberger T, Ott G, Klein T, Kalla J, Muller-Hermelink HK, Ott MM: Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. Am J Pathol. 2004, 165 (2): 481-490. 10.1016/S0002-9440(10)63313-5.PubMed CentralView ArticlePubMedGoogle Scholar
- Prevodnik VK, Lavrencak J, Horvat M, Novakovic BJ: The predictive significance of CD20 expression in B-cell lymphomas. Diagn Pathol. 2011, 6: 33-10.1186/1746-1596-6-33.PubMed CentralView ArticlePubMedGoogle Scholar
- Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004, 103 (1): 275-282. 10.1182/blood-2003-05-1545.View ArticlePubMedGoogle Scholar
- Oh S, Koo DH, Suh C, Kim S, Park BH, Kang J, Huh J: Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy. J Korean med sci. 2011, 26 (12): 1556-1562. 10.3346/jkms.2011.26.12.1556.PubMed CentralView ArticlePubMedGoogle Scholar
- Bende RJ, Smit LA, van Noesel CJ: Molecular pathways in follicular lymphoma. Leukemia. 2007, 21 (1): 18-29. 10.1038/sj.leu.2404426.View ArticlePubMedGoogle Scholar
- Ngan BY, Chen-Levy Z, Weiss LM, Warnke RA, Cleary ML: Expression in non-Hodgkin’s lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med. 1988, 318 (25): 1638-1644. 10.1056/NEJM198806233182502.View ArticlePubMedGoogle Scholar
- Lai R, Arber DA, Chang KL, Wilson CS, Weiss LM: Frequency of bcl-2 expression in non-Hodgkin’s lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia. Mod Pathol. 1998, 11 (9): 864-869.PubMedGoogle Scholar
- Kishimoto K, Kitamura T, Fujita K, Tate G, Mitsuya T: Cytologic differential diagnosis of follicular lymphoma grades 1 and 2 from reactive follicular hyperplasia: cytologic features of fine-needle aspiration smears with Pap stain and fluorescence in situ hybridization analysis to detect t(14;18)(q32;q21) chromosomal translocation. Diagn Cytopathol. 2006, 34 (1): 11-17. 10.1002/dc.20381.View ArticlePubMedGoogle Scholar
- Sekiguchi N, Kobayashi Y, Yokota Y, Kusumoto S, Tanimoto K, Watanabe T, Matsuno Y, Tobinai K: Follicular lymphoma subgrouping by fluorescence in situ hybridization analysis. Cancer sci. 2005, 96 (2): 77-82. 10.1111/j.1349-7006.2005.00014.x.View ArticlePubMedGoogle Scholar
- Gollub W, Stassek B, Huckhagel T, Bernd HW, Krokowski M, Merz H, Feller AC, Thorns C: BCL6-translocations affect the phenotype of follicular lymphomas only in the absence of t(14;18)IgH/BCL2. Anticancer Res. 2009, 29 (11): 4649-4655.PubMedGoogle Scholar
- Liu YH, Xu FP, Zhuang HG, Lai KC, Xie D, Luo DL, Li L, Luo XL, Xu J, Zhang MH, Zhang F, Li HM: Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients. Hum Pathol. 2008, 39 (6): 875-884. 10.1016/j.humpath.2007.10.013.View ArticlePubMedGoogle Scholar
- Vega F, Medeiros LJ: Chromosomal translocations involved in non-Hodgkin lymphomas. Arch Pathol Lab Med. 2003, 127 (9): 1148-1160.PubMedGoogle Scholar
- Schraders M, de Jong D, Kluin P, Groenen P, van Krieken H: Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation. J Pathol. 2005, 205 (3): 329-335. 10.1002/path.1689.View ArticlePubMedGoogle Scholar
- Jost PJ, Ruland J: Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007, 109 (7): 2700-2707.PubMedGoogle Scholar
- Bosga-Bouwer AG, van Imhoff GW, Boonstra R, van der Veen A, Haralambieva E, van den Berg A, de Jong B, Krause V, Palmer MC, Coupland R, Kluin PM, van den Berg E, Poppema S: Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood. 2003, 101 (3): 1149-1154. 10.1182/blood.V101.3.1149.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.